Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys

Journal of Neurochemistry

Volumn 109, Issue 3, 2009, Pages 826-837

  Huang, Luping Z ^a   Parameswaran, Neeraja ^a   Bordia, Tanuja ^a   Michael McIntosh, J ^b   Quik, Maryka ^a  

^a PARKINSON S INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; MPTP; Neuroprotection; Neurorestoration; Nicotine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CONOTOXIN; DOPAMINE TRANSPORTER; IODINE 125; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; MALE; MEDIAL FOREBRAIN BUNDLE; MONKEY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRIATONIGRAL DEGENERATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; COCAINE; CONOTOXINS; CORPUS STRIATUM; COTININE; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; IODINE ISOTOPES; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NICOTINE; OXIDOPAMINE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SAIMIRI; SUBSTANTIA NIGRA; TIME FACTORS;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 64349110062     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06011.x     Document Type: Article

References (50)

1. Abin-Carriquiry J. A., McGregor-Armas R., Costa G., Urbanavicius J. Dajas F. (2002) Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra. Neurotox. Res. 4, 133 139.
2. Belluardo N., Mudo G., Caniglia G., Cheng Q., Blum M. Fuxe K. (1999a) The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport 10, 3909 3913.
3. Belluardo N., Mudo G., Blum M., Cheng Q., Caniglia G., Dell'Albani P. Fuxe K. (1999b) The nicotinic acetylcholine receptor agonist (+/-)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain. Brain Res. Mol. Brain Res. 74, 98 110.
4. Belluardo N., Mudo G., Blum M., Itoh N., Agnati L. Fuxe K. (2004) Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging. Neurobiol. Aging 25, 1333 1342.
5. Bordia T., Parameswaran N., Fan H., Langston J. W., McIntosh J. M. Quik M. (2006) Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. J. Pharmacol. Exp. Ther. 319, 285 292.
6. Bordia T., Grady S. R., McIntosh J. M. Quik M. (2007) Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol. Pharmacol. 72, 52 61.
7. Brunzell D. H., Russell D. S. Picciotto M. R. (2003) In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J. Neurochem. 84, 1431 1441.
8. Cenci M. A., Lee C. S. Bjorklund A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694 2706.
9. Cenci M. A., Tranberg A., Andersson M. Hilbertson A. (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94, 515 527.
10. Cenci M. A., Whishaw I. Q. Schallert T. (2002) Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574 579.
11. Costa G., Abin-Carriquiry J. A. Dajas F. (2001) Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336 342.
12. Dajas-Bailador F. Wonnacott S. (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci. 25, 317 324.
13. Gahring L. C. Rogers S. W. (2005) Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J. 7, E885 E894.
14. Gorell J. M., Peterson E. L., Rybicki B. A. Johnson C. C. (2004) Multiple risk factors for Parkinson's disease. J. Neurol. Sci. 217, 169 174.
15. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F. Zoli M. (2007) Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol. 74, 1102 1111.
16. Grady S. R., Salminen O., Laverty D. C., Whiteaker P., McIntosh J. M., Collins A. C. Marks M. J. (2007) The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem. Pharmacol. 74, 1235 1246.
17. Janson A. M., Fuxe K., Agnati L. F., Kitayama I., Harfstrand A., Andersson K. Goldstein M. (1988) Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 455, 332 345.
18. Lai A., Parameswaran N., Khwaja M., Whiteaker P., Lindstrom J. M., Fan H., McIntosh J. M., Grady S. R. Quik M. (2005) Long-term nicotine treatment decreases striatal alpha6* nicotinic acetylcholine receptor sites and function in mice. Mol. Pharmacol. 67, 1639 1647.
19. Lowry O. H., Rosebrough N. J., Farr A. L. Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
20. Mao D., Perry D. C., Yasuda R. P., Wolfe B. B. Kellar K. J. (2008) The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J. Neurochem. 104, 446 456.
21. Massey K. A., Zago W. M. Berg D. K. (2006) BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons. Mol. Cell. Neurosci. 33, 381 388.
22. Matta S. G., Balfour D. J., Benowitz N. L. et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl.) 190, 269 319.
23. Meshul C. K., Kamel D., Moore C., Kay T. S. Krentz L. (2002) Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats. Exp. Neurol. 175, 257 274.
24. Mugnaini M., Garzotti M., Sartori I., Pilla M., Repeto P., Heidbreder C. A. Tessari M. (2006) Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. Neuroscience 137, 565 572.
25. Nguyen H. N., Rasmussen B. A. Perry D. C. (2004) Binding and functional activity of nicotinic cholinergic receptors in selected rat brain regions are increased following long-term but not short-term nicotine treatment. J. Neurochem. 90, 40 49.
26. O'Neill M. J., Murray T. K., Lakics V., Visanji N. P. Duty S. (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 1, 399 411.
27. Perez X. A., Bordia T., McIntosh J. M., Grady S. R. Quik M. (2008) Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(Nonalpha4)beta2* nAChR expression and function. Mol. Pharmacol. 74, 844 853.
28. Perry D. C., Mao D., Gold A. B., McIntosh J. M., Pezzullo J. C. Kellar K. J. (2007) Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. J. Pharmacol. Exp. Ther. 322, 306 315.
29. Picciotto M. R. Zoli M. (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci. 13, 492 504.
30. Pietila K. Ahtee L. (2000) Chronic nicotine administration in the drinking water affects the striatal dopamine in mice. Pharmacol. Biochem. Behav. 66, 95 103.
31. Pietila K., Salminen O., Leikola-Pelho T. Ahtee L. (1996) Tolerance to nicotine's effects on striatal dopamine metabolism in nicotine-withdrawn mice. Eur. J. Pharmacol. 318, 17 22.
32. Quik M., Polonskaya Y., Kulak J. M. McIntosh J. M. (2001) Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. J. Neurosci. 21, 5494 5500.
33. Quik M., Sum J. D., Whiteaker P., McCallum S. E., Marks M. J., Musachio J., McIntosh J. M., Collins A. C. Grady S. R. (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol. Pharmacol. 63, 1169 1179.
34. Quik M., Vailati S., Bordia T., Kulak J. M., Fan H., McIntosh J. M., Clementi F. Gotti C. (2005) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine or L-DOPA. Mol. Pharmacol. 67, 32 41.
35. Quik M., Chen L., Parameswaran N., Xie X., Langston J. W. McCallum S. E. (2006a) Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26, 4681 4689.
36. Quik M., Parameswaran N., McCallum S. E., Bordia T., Bao S., McCormack A., Kim A., Tyndale R. F., Langston J. W. Di Monte D. A. (2006b) Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98, 1866 1875.
37. Quik M., Bordia T. O'Leary K. (2007a) Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol. 74, 1224 1234.
38. Quik M., O'Neill M. Perez X. A. (2007b) Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci. 28, 229 235.
39. Ritz B., Ascherio A., Checkoway H., Marder K. S., Nelson L. M., Rocca W. A., Ross G. W., Strickland D., Van Den Eeden S. K. Gorell J. (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch. Neurol. 64, 990 997.
40. Ryan R. E., Ross S. A., Drago J. Loiacono R. E. (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 132, 1650 1656.
41. Salminen O., Murphy K. L., McIntosh J. M., Drago J., Marks M. J., Collins A. C. Grady S. R. (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65, 1526 1535.
42. Shytle R. D., Mori T., Townsend K., Vendrame M., Sun N., Zeng J., Ehrhart J., Silver A. A., Sanberg P. R. Tan J. (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89, 337 343.
43. Singh N., Pillay V. Choonara Y. E. (2007) Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81, 29 44.
44. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Lopez-Real A. M. Labandeira-Garcia J. L. (2002) Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem. Pharmacol. 64, 125 135.
45. Sparks J. A. Pauly J. R. (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology (Berl.) 141, 145 153.
46. Thacker E. L., O'Reilly E. J., Weisskopf M. G., Chen H., Schwarzschild M. A., McCullough M. L., Calle E. E., Thun M. J. Ascherio A. (2007) Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68, 764 768.
47. Tracey K. J. (2007) Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117, 289 296.
48. Vincler M., Wittenauer S., Parker R., Ellison M., Olivera B. M. McIntosh J. M. (2006) Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. U S A 103, 17880 17884.
49. Visanji N. P., O'Neill M. J. Duty S. (2006) Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51, 506 516.
50. Zhou X., Nai Q., Chen M., Dittus J. D., Howard M. J. Margiotta J. F. (2004) Brain-derived neurotrophic factor and trkB signaling in parasympathetic neurons: relevance to regulating alpha7-containing nicotinic receptors and synaptic function. J. Neurosci. 24, 4340 4350.